Coronary Plaque Morphology and the Anti-Inflammatory Impact of Atorvastatin: A Multicenter 18 F-Fluorodeoxyglucose Positron Emission Tomographic/Computed Tomographic Study
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background—: Nonobstructive coronary plaques manifesting high-risk morphology (HRM) associate with an increased risk of adverse clinical cardiovascular events. We sought to test the hypothesis that statins have a greater anti-inflammatory effect within coronary plaques containing HRM. Methods and Results—: In this prospective multicenter study, 55 subjects with or at high risk for atherosclerosis underwent 18 F-fluorodeoxyglucose positron emission tomographic/computed tomographic imaging at baseline and after 12 weeks of treatment with atorvastatin. Coronary arterial inflammation ( 18 F-fluorodeoxyglucose uptake, expressed as target-to-background ratio) was assessed in the left main coronary artery (LMCA). While blinded to the PET findings, contrast-enhanced computed tomographic angiography was performed to characterize the presence of HRM (defined as noncalcified or partially calcified plaques) in the LMCA. Arterial inflammation (target-to-background ratio) was higher in LMCA segments with HRM than those without HRM (mean±SEM: 1.95±0.43 versus 1.67±0.32 for LMCA with versus without HRM, respectively; P =0.04). Moreover, atorvastatin treatment for 12 weeks reduced target-to-background ratio more in LMCA segments with HRM than those without HRM (12 week-baseline Δtarget-to-background ratio [95% confidence interval]: −0.18 [−0.35 to −0.004] versus 0.09 [−0.06 to 0.26]; P =0.02). Furthermore, this relationship between coronary plaque morphology and change in LMCA inflammatory activity remained significant after adjusting for baseline low-density lipoprotein and statin dose (β=−0.27; P =0.038). Conclusions—: In this first study to evaluate the impact of statins on coronary inflammation, we observed that the anti-inflammatory impact of statins is substantially greater within coronary plaques that contain HRM features. These findings suggest an additional mechanism by which statins disproportionately benefit individuals with more advanced atherosclerotic disease. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00703261.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Bittencourt, M. S., Blaha, M. J., Blankstein, R., Budoff, M., Vargas, J. D., Blumenthal, R. S., Agatston, A. S., & Nasir, K. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.08.1640 · Cited by 70 · cited 1×
“Accordingly, the findings of this study provide additional support for the hypothesis that assessment of atherosclerosis, including arterial wall inflammatory activity, might help to identify individuals who would derive the greatest benefit from statin therapy (even among individuals already deemed to be at increased…”
Result
Cited by
Plaque Calcification During Atherosclerosis Progression and Regression
Shioi, A., & Ikari, Y. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17020 · Cited by 271
Effect of statins on atherosclerotic plaque
Almeida, S. O., & Budoff, M. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.01.001 · Cited by 263
Psychosocial stress and cardiovascular disease
Dar, T., Radfar, A., Abohashem, S., Pitman, R. K., Tawakol, A., & Osborne, M. T. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0724-5 · Cited by 248
Self-citationCalcium deposition within coronary atherosclerotic lesion: Implications for plaque stability
Jinnouchi, H., Sato, Y., Sakamoto, A., Cornelissen, A., Mori, M., Kawakami, R., Gadhoke, N. V., Kolodgie, F. D., Virmani, R., & Finn, A. V. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.05.017 · Cited by 195
FDG PET/CT of the non-malignant liver in an increasingly obese world population
Keramida, G., & Peters, A. M. (2020) · Clinical Physiology and Functional Imaging · doi:10.1111/cpf.12651 · Cited by 25
Lai, R., Ju, J., Lin, Q., & Xu, H. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.600497 · Cited by 19
Metadata
- Authors
- Singh, P., Emami, H., Subramanian, S., Maurovich-Horvat, P., Marincheva-Savcheva, G., Medina, H. M., Abdelbaky, A., Alon, A., Shankar, S. S., Rudd, J. H. F., Fayad, Z. A., Hoffmann, U., & Tawakol, A.
- Venue
- Circulation: Cardiovascular Imaging
- Published
- 2016-12
- Volume
- 9
- Issue
- 12
- ISSN
- 1941-9651 (ISSN-L)
- 1942-0080
- OpenAlex
- W2563322037
- Cited by
- 57
- References
- 3
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.